Reprogramming using microRNA-302 improves drug sensitivity in hepatocellular carcinoma cells

Area of Science:

• Stem Cell Biology
• Cancer Research
• Epigenetics

Background:

• Oct4, Sox2, Klf4, and c-Myc (OKSM) reprogramming has risks.
• MicroRNA (miRNA)-mediated reprogramming is an alternative.
• This study investigates miRNA reprogramming in hepatocellular carcinoma (HCC).

Purpose of the Study:

• To evaluate the efficacy of miRNA-mediated reprogramming in HCC cells.
• To assess if miR-302 can reprogram HCC cells into induced pluripotent stem cell (iPSC)-like cells.
• To determine the mechanism of drug sensitization by miR-302 reprogramming.

Main Methods:

• miR-302 was transfected into HCC cells.
• Cells were incubated in ES medium for 3 weeks.
• Characterization included pluripotency markers, proliferation, apoptosis, EMT markers, miRNA expression, c-Myc, H3K4 methylation, germ layer differentiation, and AOF2 (LSD1/KDM1) targeting.

Main Results:

• iPSC-like spheres with high NANOG/OCT4, low proliferation, high apoptosis, and low EMT markers were obtained.
• Drug sensitization was observed.
• miR-302 down-regulated AOF2, leading to c-Myc repression and increased H3K4 methylation.

Conclusions:

• miR-302 effectively reprograms HCC cells into iPSC-like cells.
• This reprogramming enhances drug sensitivity.
• The mechanism involves AOF2 down-regulation, H3K4 methylation, and c-Myc repression.